Date: 2016-03-29
Type of information: Collaboration agreement
Compound: 3DEXPERIENCE platform
Company: Dassault Systèmes (France) Inserm (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 29, 2016, Dassault Systèmes and the French National Institute of Health and Medical Research (Inserm), announced the signature of a joint agreement to accelerate clinical research programs by deploying a virtual collaborative platform. The agreement will draw from the expertise of each organization to offer new perspectives for addressing scientific and health challenges of the 21st century. Inserm will use Dassault Systèmes’ 3DEXPERIENCE platform to conduct its strategic biomedical research programs in the areas of aging, cancer, genomics and microbiota. The platform provides Inserm with an integrated virtual environment for open collaborative research, unified laboratory management and biological and chemical modeling and simulation from Dassault Systèmes’
flagship brand dedicated to scientific excellence, BIOVIA.
In turn, Dassault Systèmes will leverage big data from Inserm’s research programs to calibrate and validate scientific models that can be applied to future technologies for the clinical research domain. These models will enable the company to develop next-generation industry solution experiences targeting clinical trials, to accelerate decision-making and to enable earlier efficacy and safety demonstration with virtual trials.
Financial terms:
Latest news:
